Crescendo has a successful global, strategic, multi-target collaboration and license agreement with Takeda Pharmaceutical Company Ltd for the development and commercialisation of Humabody® drugs for the treatment of cancer indications with high unmet need. Crescendo will use its proprietary transgenic VH platform and expertise in formatting to identify and rapidly assemble human VH ‘building blocks’ into optimally configured Humabody® therapeutics against multiple targets selected by Takeda. Targets selected will incorporate both Humabody® Drug Conjugates (HDC) and Immuno-Oncology (IO) modulators. This first partnership validates the potential of Crescendo’s transgenic platform and our capabilities to rapidly assemble and configure small, differentiated Humabody® therapeutics, opening routes to novel biology.
Crescendo also has collaborations with several companies that offer next generation payloads. These are focused on combining them with Humabodies to generate HDCs (Humabody® Drug Conjugates).
In addition Crescendo has ongoing collaborative interactions with a number of key academic groups with the aim of further exploring the differentiating features of our Humabody® therapeutics.